Amalgamated Bank increased its holdings in shares of Insulet Co. (NASDAQ:PODD – Free Report) by 3.5% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 18,818 shares of the medical instruments supplier’s stock after purchasing an additional 634 shares during the quarter. Amalgamated Bank’s holdings in Insulet were worth $3,001,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in PODD. Allworth Financial LP boosted its stake in Insulet by 104.5% in the third quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 92 shares in the last quarter. BluePath Capital Management LLC acquired a new stake in shares of Insulet in the 3rd quarter valued at about $31,000. First Manhattan Co. purchased a new position in Insulet during the 4th quarter worth approximately $35,000. Massmutual Trust Co. FSB ADV increased its position in Insulet by 228.8% during the third quarter. Massmutual Trust Co. FSB ADV now owns 263 shares of the medical instruments supplier’s stock worth $42,000 after buying an additional 183 shares during the period. Finally, HM Payson & Co. purchased a new stake in Insulet in the third quarter valued at approximately $48,000.
Insider Buying and Selling
In other Insulet news, Director Shacey Petrovic sold 20,000 shares of the stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $164.33, for a total value of $3,286,600.00. Following the completion of the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at $421,835.11. The sale was disclosed in a filing with the SEC, which is available at this link. 0.90% of the stock is owned by insiders.
Wall Street Analyst Weigh In
Insulet Price Performance
Insulet stock opened at $192.55 on Friday. The company has a debt-to-equity ratio of 2.26, a quick ratio of 2.35 and a current ratio of 3.26. Insulet Co. has a one year low of $125.82 and a one year high of $335.91. The company has a market cap of $13.45 billion, a P/E ratio of 112.60, a price-to-earnings-growth ratio of 2.13 and a beta of 1.05. The business has a fifty day moving average of $202.87 and a two-hundred day moving average of $188.65.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.
- Five stocks we like better than Insulet
- What is a SEC Filing?
- MarketBeat Week in Review – 2/5 – 2/9
- Canadian Penny Stocks: Can They Make You Rich?
- Cloudflare results spark analysts reset: 25% upside ahead
- What Are Defense Contractor Stocks? How to Invest in Defense
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.